Thyroid carcinoma is the most common endocrine malignancy. Approximately 90% of non-medullary thyroid malignancies are classified as well-differentiated thyroid carcinomas. Even though this type of tumor is not aggressive and usually curable after therapy, recurrence develops in 20-40% and progression to cellular de-differentiation occurs in up to 30% of patients. Poorly differentiated cancers are characterized by loss of thyroid-specific functions and properties, such as the capacity to concentrate radioiodide. Therapeutic options for de-differentiated thyroid cancer are limited and generally not […]